COMMUNIQUÉS West-GlobeNewswire

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
15/07/2026
Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
15/07/2026
TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage [...]
Sienna Announces July Dividend
15/07/2026
MARKHAM, Ontario, July 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson [...]
iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
15/07/2026
New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows. Beijing, China, July [...]
Attovia Therapeutics Appoints John W. Smither to Board of Directors
15/07/2026
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company [...]
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
15/07/2026
AI-powered Initiative Aims to Enhance Customer Engagement, Accelerate Commercial Execution and Support Long-Term Growth Visit booth #112 in the Sparkle Ballroom at Fontainebleau Miami Beach for a live demonstration of [...]
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
15/07/2026
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular [...]
NOMAD Power Solutions Strengthens Subsidiary Executive Leadership
15/07/2026
Huda Almashhadany Joins Team as Chief of Product & VP of Operations, Company Names Brian Dockendorf as Director of Service Boca Raton, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or [...]
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
15/07/2026
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
15/07/2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, [...]
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
15/07/2026
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data [...]
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company [...]
Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
15/07/2026
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data demonstrate favorable [...]
WONDERLAB Spotlights Gut Health and Innate Immunity, Featuring Its Proprietary Strain GOLDGUT-M520
15/07/2026
SHENZHEN, China, July 15, 2026 (GLOBE NEWSWIRE) -- On May 21, 2026, WONDERLAB ran a public science-education series on gut health and immunity, featuring its proprietary strain GOLDGUT-M520. The program included an [...]
45,611 Orion Corporation A shares converted into B shares
15/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JULY 2026 at 9.00 EEST 45,611 Orion Corporation A shares converted into B shares In accordance with [...]
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
15/07/2026
Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for survodutide and pipeline [...]
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
15/07/2026
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus 1 If approved, Gazyva/Gazyvaro will be the [...]
Closing of Previously Announced Restructuring Transaction in Connection with CCAA Proceedings
15/07/2026
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 [...]

Pages